Home > Oceania > New Zealand > New Zealand Healthcare Professional 10-10-2023

This website is intended for New Zealand Healthcare Professionals only.

Each capsule contains 200 mg molnupiravir
Each bottle contains 40 capsules
Store below 30ºC
Lagevrio is a fully funded medicine – restrictions apply.

Have a question about an MSD Product or want to report an Adverse Event or Quality Issue?

Phone: 0800 500 673
Monday – Friday 9:30 a.m. – 5:30 p.m. Australian Eastern Daylight Time

Email: dpoc.australia@msd.com

MSD New Zealand Address

Merck Sharp & Dohme (New Zealand) Limited. Level 3, 123 Carlton Gore Road, Newmarket, Auckland

Lagevrio® (molnupiravir) is a restricted medicine (pharmacist-only medicine) for use in the treatment of COVID-19 and is available as 200 mg capsules.

INDICATION: Provisional consent for the treatment of mild to moderate COVID-19 in adults (≥18 years) who are at increased risk of progressing to severe COVID-19, hospitalisation or death.

CONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients.

PRECAUTIONS: Use in pregnancy is not recommended; consider the need for a pregnancy test before initiating treatment in women of childbearing potential who are sexually active. It is recommended that sexually active women of childbearing potential use contraception during and for 4 days after the last dose, and that men who are sexually active with a partner of childbearing potential use an adequate form of contraception during and for 3 months after treatment. Breastfeeding is not recommended during treatment and for 4 days after the last dose. Not recommended in paediatric patients. Hypersensitivity reactions have been reported; if signs and symptoms of a clinically significant hypersensitivity reaction occur, immediately discontinue Lagevrio and initiate appropriate medications and/or supportive care.

INTERACTIONS: No drug interactions have been identified based on the limited available data.

ADVERSE EVENTS: Common: diarrhoea, nausea, dizziness. The following have been reported in post- marketing experience: hypersensitivity, angioedema, erythema, pruritus, rash, urticaria, vomiting.

DOSAGE AND ADMINISTRATION: Adults: 800 mg (four 200 mg capsules) taken orally every 12 hours for 5 days, with or without food. Lagevrio should be administered as soon as possible after a diagnosis of COVID-19 has been made and within 5 days of symptom onset. Based on Data Sheet dated 13 September 2023.

Please review the Lagevrio Data Sheet. The Data Sheet is available at www.medsafe.govt.nz.

(“By continuing, you will be directed to another website, which MSD has not developed. We do not review or control the content of any third-party website. We do not endorse and are not responsible for the accuracy, content, practices, or standards of any third-party sources.”)

Lagevrio is a fully funded medicine – restrictions apply.


Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

NZ-LAG-00103 First issued November 2023 TAPS DA 2339KN.